X
PCVX icon

Xponance’s Vaxcyte PCVX Stock Holding History

Xponance’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759K Buy
13,050
+1,652
+14% +$89.7K ﹤0.01% 910
2026
Q1 		$662K Buy
11,398
+2,318
+26% +$126K ﹤0.01% 896
2025
Q4 		$419K Buy
9,080
+69
+0.8% +$3.09K ﹤0.01% 1020
2025
Q3 		$325K Sell
9,011
-708
-7% -$23.5K ﹤0.01% 1121
2025
Q2 		$316K Buy
9,719
+399
+4% +$13.1K ﹤0.01% 1120
2025
Q1 		$352K Buy
9,320
+415
+5% +$33.2K ﹤0.01% 1044
2024
Q4 		$729K Buy
8,905
+1,052
+13% +$104K 0.01% 834
2024
Q3 		$897K Buy
7,853
+939
+14% +$84.6K 0.01% 733
2024
Q2 		$522K Buy
6,914
+465
+7% +$31.7K 0.01% 901
2024
Q1 		$441K Buy
6,449
+777
+14% +$53.8K ﹤0.01% 980
2023
Q4 		$356K Buy
5,672
+163
+3% +$8.46K ﹤0.01% 1025
2023
Q3 		$281K Buy
5,509
+97
+2% +$4.79K ﹤0.01% 1052
2023
Q2 		$270K Buy
+5,412
New +$257K ﹤0.01% 1072

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Xponance's PCVX Position: Q2 2026 in Review

Xponance increased its Vaxcyte (PCVX) stake by 14% in Q2 2026, buying an estimated $89.7K and bringing the position to 13,050 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

Xponance first reported a position in PCVX in Q2 2023 and has held it in 13 quarters since. The position peaked at $897K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Xponance held 13,050 shares of Vaxcyte worth $759K as of Q2 2026.
  • Xponance bought 1,652 Vaxcyte shares in Q2 2026, an estimated $89.7K.
  • Vaxcyte made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #910 holding.
  • Xponance first reported a position in Vaxcyte in Q2 2023 and has held it in 13 quarters since.
  • Xponance's Vaxcyte position peaked at $897K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.